Green P, Kamensky B, Yavin E
Department of Neurobiology, Weizmann Institute of Science, Rehovot, Israel.
J Neurosci Res. 1997 May 1;48(3):264-72. doi: 10.1002/(sici)1097-4547(19970501)48:3<264::aid-jnr9>3.0.co;2-d.
A procedure for intraamniotic ethyl-docosahexaenoate (Et-DHA) administration was used to restore the docosahexaenoic acid (DHA; 22:6 n-3) levels in n-3-deficient fetal rats. The state of deficiency, characterized by a 34% and 60% decrease in DHA content of fetal brain and liver, respectively, was attained by feeding the pregnant dams from day 8 and up to 20 days gestation, with an n-3 linolenic acid-deprived diet. After a single intraamniotic administration of Et-DHA on day 18 or 19, a rapid increase in both fetal brain and liver DHA was achieved. This increase was accompanied by a decrease in the docosapentaenoic acid (DPA; 22:5 n-6) level. After 48 hr following Et-DHA administration, the major phospholipids (PLs) phosphatidylserine (PS), phosphatidylethanolamine (PE), and phosphatidylcholine (PC), together accounting for more than 90% of total lipid phosphorus in sunflower oil (SFO)-treated animals, regained the DHA content to levels similar to control animals in both fetal brain and liver tissues. Unlike brain, however, most of the DHA content in liver PLs was restored by 24 hr, suggesting that the fetal liver may have a higher metabolic turnover. The DHA/DPA ratio was used to assess the degree of DHA correction. Fetal brain PS, PC, and PE ratios following Et-DHA administration grew steadily over a period of 48 hr but reached only approximately 60% of the control levels. Liver PS regained a value similar to the control, while those of PC and PE were 33% and 46% lower than the controls, respectively. Alterations in the PL polar head-group composition were observed following the dietary manipulations and Et-DHA administration. Although the intraamniotic injection is an invasive approach, the ability to rapidly enhance DHA acylation during intrauterine life may hold potential clinical value whenever an indication for DHA deficiency exists.
采用羊膜腔内注射二十二碳六烯酸乙酯（Et-DHA）的方法来恢复n-3缺乏的胎鼠体内二十二碳六烯酸（DHA；22:6 n-3）的水平。通过在妊娠第8天至20天给怀孕母鼠喂食缺乏n-3亚麻酸的饲料，造成胎鼠缺乏状态，其特征是胎鼠脑和肝脏中DHA含量分别降低34%和60%。在第18天或19天进行单次羊膜腔内注射Et-DHA后，胎鼠脑和肝脏中的DHA均迅速增加。这种增加伴随着二十二碳五烯酸（DPA；22:5 n-6）水平的降低。在注射Et-DHA后48小时，主要磷脂（PLs）磷脂酰丝氨酸（PS）、磷脂酰乙醇胺（PE）和磷脂酰胆碱（PC），在向日葵油（SFO）处理的动物中，它们占总脂质磷的90%以上，胎鼠脑和肝脏组织中的DHA含量恢复到与对照动物相似的水平。然而，与脑不同的是，肝脏PLs中的大部分DHA含量在24小时内恢复，这表明胎鼠肝脏可能具有更高的代谢周转率。DHA/DPA比值用于评估DHA校正程度。注射Et-DHA后，胎鼠脑PS、PC和PE比值在48小时内稳步上升，但仅达到对照水平的约60%。肝脏PS恢复到与对照相似的值，而PC和PE的值分别比对照低33%和46%。在饮食干预和注射Et-DHA后，观察到PL极性头部基团组成的变化。尽管羊膜腔内注射是一种侵入性方法，但在子宫内生活期间快速增强DHA酰化的能力，在存在DHA缺乏指征时可能具有潜在的临床价值。
